A Phase 3 Study of I-Metaiodobenzylguanidine (I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Go Back to All Clinical Trials

A Phase 3 Study of I-Metaiodobenzylguanidine (I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Neuroblastoma
Age: Between 1 - 30 Years
Gender: Male or Female

Other Inclusion Criteria:

1) Patients who are diagnosed with neuroblastoma or ganglioneuroblastoma (nodular).

You may not be eligible for this study if the following are true:

1) Patients who have an INRG Stage L2 tumor without amplification of MYCN regardless of tumor histology.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies